As an intellectual property boutique, it’s not unusual for Lerner, David, Littenberg, Krumholz & Mentlik to handle numerous complex and high-stakes IP disputes over the course of a year, and that remained true in 2017. Aside from successfully representing New York University in a research and license agreement dispute with Pfizer, the firm’s litigators successfully represented clients on both sides of patent-review proceedings: Lerner David prevailed at the Federal Circuit defending generic drugmaker Dr. Reddy’s Laboratories, and at the trial court level won invalidation on behalf of Amneal, another generic drugmaker.

** The responses were provided by co-managing partner William Mentlik, and litigation partners Bruce Sales, Tedd Van Buskirk, Roy Wepner, Greg Gewirtz and Stephen Roth. **